Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine

References

• Alessandrini M, Asfaha S, Dodgen TM, et al. (2013). Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 45:253–275
   PubMed Web of Science ®Google Scholar
• Alessandrini M, Pepper MS. (2014). Priority pharmacogenetics for the African continent: Focus on CYP450. Pharmacogenomics 15:385–400
   PubMed Web of Science ®Google Scholar
• Bélanger AS, Caron P, Harvey M, et al. (2009). Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos 37:1793–1796
   PubMed Web of Science ®Google Scholar
• Brown KC, Hosseinipour MC, Hoskins JM, et al. (2012). Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13:113–121
   PubMed Web of Science ®Google Scholar
• Ciccacci C, Borgiani P, Ceffa S, et al. (2010). Nevirapine-induced hepatotoxicity and pharmacogenetics: A retrospective study in a population from Mozambique. Pharmacogenomics 11:23–31
   PubMed Web of Science ®Google Scholar
• Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209–224
   PubMed Web of Science ®Google Scholar
• Dandara C, Swart M, Mpeta B, et al. (2014). Cytochrome P450 pharmacogenetics in African populations: Implications for public health. Expert Opin Drug Metab Toxicol 10:769–785
   PubMed Web of Science ®Google Scholar
• De Wit E, Delport W, Rugamika CE, et al. (2010). Genome-wide analysis of the structure of the South African coloured population in the Western Cape. Hum Genet 128:145–153
   PubMed Web of Science ®Google Scholar
• Department of Health (DOH), Republic of South Africa. (2013). The South African antriretroviral treatment guidelines. Available from: http://www.sahivsoc.org/upload/documents/2013%20ART%20GuidelinesShort%20Combined%20FINAL%20draft%20guidelines%2014%20March%202013.pdf [last accessed 16 Apr 2014]
   Google Scholar
• Desta Z, Saussele T, Ward B, et al. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8:547–558
   PubMed Web of Science ®Google Scholar
• Di Iulio J, Fayet A, Arab-Alameddine M, et al. (2009). In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics 19:300–309
   PubMed Web of Science ®Google Scholar
• Elens L, Vandercam B, Yombi JC, et al. (2010). Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 11:1223–1234
   PubMed Web of Science ®Google Scholar
• Gatanga H, Hayashida T, Tsuchiya K, et al. (2007). Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 45:1230–1237
   PubMed Web of Science ®Google Scholar
• Gounden V, Van Niekerk C, Snyman T, George JA. (2010). Presence of the CYP2B6 516G>T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32
   PubMed Web of Science ®Google Scholar
• Gross R, Aplenc R, Tenhave T, et al. (2008). Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr 49:336–337
   PubMed Web of Science ®Google Scholar
• Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 3:136–158
   PubMed Web of Science ®Google Scholar
• Gyamfi MA, Fujieda M, Kiyotani K, et al. (2005). High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana. Eur J Clin Pharmacol 60:855–857
   PubMed Web of Science ®Google Scholar
• Haas DW, Bartlett JA, Andersen JW, et al. (2006). Pharmacogenetics of nevirapine-associated hepatotoxicity: An Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783–786
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, et al. (2004). Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 18:2391–2400
   PubMed Web of Science ®Google Scholar
• Ikediobi O, Aouizerat B, Xiao Y, et al. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum Genomics 5:265–282
   PubMedGoogle Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2007). Pharmacogenetics of the P450s. In: Daly A, ed. Drug metabolizing enzymes: Fundamentals, study methods, recent advances and clinical significance. The Biomedical & Life Sciences Collection. London: Henry Stewart Talks Ltd. Available from: http://0-hstalks.com.innopac.up.ac.za/?t=BL0091124 [last accessed 28 Oct 2014]
   Google Scholar
• Jamshidi Y, Moreton M, Mckeown DA, et al. (2010). Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: Implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 65:2614–2619
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS. (2011). UNAIDS World AIDS Day Report 2011. UNAIDS. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf [last accessed 20 Apr 2014]
   Google Scholar
• Klein K, Lang T, Saussele T, et al. (2005). Genetic variability of CYP2B6 in populations of African and Asian origin: Allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 15:861–873
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, et al. (2009a). CYP2B6 (c.516G–>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67:427–436
   PubMed Web of Science ®Google Scholar
• Kwara A, Lartey M, Sagoe KW, et al. (2009b). CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101–2106
   PubMed Web of Science ®Google Scholar
• Li J, Menard V, Benish RL, et al. (2012). Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: Implications for HIV/AIDS treatment. Pharmacogenomics 13:555–570
   PubMed Web of Science ®Google Scholar
• Mahungu TW, Johnson MA, Owen A, Back DJ. (2009). The impact of pharmacogenetics on HIV therapy. Int J STD AIDS 20:145–151
   PubMed Web of Science ®Google Scholar
• Maimbo M, Kiyotani K, Mushiroda T, et al. (2012). CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68:267–271
   PubMed Web of Science ®Google Scholar
• Mehlotra RK, Bockarie MJ, Zimmerman PA. (2007). CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: Implications for HIV/AIDS treatment. Br J Clin Pharmacol 64:391–395
   PubMed Web of Science ®Google Scholar
• Michaud V, Bar-Magen T, Turgeon J, et al. (2012). The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803–833
   PubMed Web of Science ®Google Scholar
• Mukonzo JK, Röshammar D, Waako P, et al. (2009). A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68:690–699
   PubMed Web of Science ®Google Scholar
• Murray CJ, Vos T, Lozano R, et al. (2013). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223
   Web of Science ®Google Scholar
• Ngaimisi E, Habtewold A, Minzi O, et al. (2013). Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 8:e67946
   PubMed Web of Science ®Google Scholar
• Nyakutira C, Roshammar D, Chigutsa E, et al. (2008). High prevalence of the CYP2B6 516G>T (*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64:357–365
   PubMed Web of Science ®Google Scholar
• Parathyras J, Gebhardt S, Hillermann-Rebello R, et al. (2009). A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups. J Hum Genet 54:261–265
   PubMed Web of Science ®Google Scholar
• Penzak SR, Kabuye G, Mugyenyi P, et al. (2007). Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 8:86–91
   PubMed Web of Science ®Google Scholar
• Radloff R, Gras A, Zanger UM, et al. (2013). Novel CYP2B6 enzyme variants in a Rwandese population: Functional characterization and assessment of in silico prediction tools. Hum Mutat 34:725–734
   PubMed Web of Science ®Google Scholar
• Riska P, Lamson M, MacGregot T, et al. (1999). Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27:895–901
   PubMed Web of Science ®Google Scholar
• Saeki M, Saito Y, Jinno H, et al. (2004). Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos 32:1048–1054
   PubMed Web of Science ®Google Scholar
• Sarfo FS, Zhang Y, Egan D, et al. (2014). Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother 69:491–499
   PubMed Web of Science ®Google Scholar
• Schoedel KA, Hoffmann EB, Rao Y, et al. (2004). Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615–626
   PubMedGoogle Scholar
• Swart M, Skelton M, Ren Y, et al. (2013). High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 23:415–427
   PubMed Web of Science ®Google Scholar
• Swart M, Skelton M, Wonkam A, et al. (2012). CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 Polymorphisms in Two Bantu-Speaking Populations from Cameroon and South Africa: Implications for Global Pharmacogenetics. Curr Pharmacogen Pers Med 10:43–53
   Google Scholar
• Thorn CF, Lamba JK, Lamba V, et al. (2010). PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 20:520–523
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Reed FA, Friedlaender FR, et al. (2009). The genetic structure and history of Africans and African Americans. Science 324:1035–1044
   PubMed Web of Science ®Google Scholar
• Wang J, Sonnerborg A, Rane A, et al. (2006). Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 16:191–198
   PubMed Web of Science ®Google Scholar
• Ward BA, Gorski JC, Jones DR, et al. (2003). The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300
   PubMed Web of Science ®Google Scholar
• Warnich L, Drögemöller BI, Pepper MS, et al. (2011). Pharmacogenomic research in South Africa: Lessons learned and future opportunities in the Rainbow Nation. Curr Pharmacogenomics Person Med 9:191–207
   PubMedGoogle Scholar
• Whirl-Carrillo M, McDonagh EM, Herbert JM, et al. (2012). Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–417
   PubMed Web of Science ®Google Scholar